DelveInsight’s “Relapsing / Refractory Multiple Myeloma (RRMM) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Relapsing / Refractory Multiple Myeloma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Relapsing / Refractory Multiple Myeloma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Relapsing / Refractory Multiple Myeloma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Relapsing / Refractory Multiple Myeloma (RRMM): An Overview
Multiple myeloma (MM) is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. The immune system is made up of several types of cells that work together to fight infections and other diseases. Lymphocytes (lymph cells) are one of the main types of white blood cells in the immune system and include T cells and B cells. Lymphocytes are in many areas of the body, such as lymph nodes, the bone marrow, the intestines, and the bloodstream.
In Relapsing / Refractory Multiple Myeloma (RRMM), the cancer returns after treatment, or after a period of remission. Refractory multiple myeloma refers to cancer that is not responding to standard therapy. There are many potential mechanisms that may impact and promote treatment resistance.
Relapsing / Refractory Multiple Myeloma (RRMM) Market Key Facts
As per the viewpoints of Lawrence in a study titled, “Multiple Myeloma Incidence Increasing Worldwide, Especially in the US”, the global burden of multiple myeloma has increased uniformly in the last 30 years. In 2016, there were about 130,000 cases of myeloma, translating to an age-standardized incidence rate of 2.1 per 100,000 persons.
Myeloma Patients Europe highlighted that in Europe about 40,000 people were diagnosed with myeloma in 2015, and this number is predicted to increase to almost 46,000 by 2025. Myeloma can affect adults of any age, but it is much more frequent in people aged over 65 years and in men rather than women.
Relapsing / Refractory Multiple Myeloma (RRMM) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Relapsing / Refractory Multiple Myeloma pipeline therapies. It also thoroughly assesses the Relapsing / Refractory Multiple Myeloma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Relapsing / Refractory Multiple Myeloma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Relapsing / Refractory Multiple Myeloma (RRMM) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Relapsing / Refractory Multiple Myeloma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Relapsing / Refractory Multiple Myeloma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Relapsing / Refractory Multiple Myeloma Epidemiology, Segmented as –
Incident cases of Multiple Myeloma (MM) in the 7MM (2019–2032)
Gender-specific Incidence of Multiple Myeloma (MM) in the 7MM (2019–2032)
Age-specific Incidence of Multiple Myeloma (MM) in the 7MM (2019–2032)
Treatable Cases of Multiple Myeloma (MM) Population According to First to Third Line of Treatment in the 7MM (2019–2032)
Treatable Cases of Triple Refractory Multiple Myeloma (MM) in the 7MM (2019–2032)
Relapsing / Refractory Multiple Myeloma (RRMM) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Relapsing / Refractory Multiple Myeloma market or expected to be launched during the study period. The analysis covers the Relapsing / Refractory Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Relapsing / Refractory Multiple Myeloma drugs based on their sale and market share.
The report also covers the Relapsing / Refractory Multiple Myeloma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Relapsing / Refractory Multiple Myeloma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Relapsing / Refractory Multiple Myeloma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-market
Relapsing / Refractory Multiple Myeloma (RRMM) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Relapsing Refractory Multiple Myeloma. Currently, Bristol-Myers Squibb is leading the therapeutics market with its Relapsing Refractory Multiple Myeloma drug candidates in the most advanced stage of clinical development.
“On June 13th, 2023, CellCentric announces that the US Food and Drug Administration (FDA) has granted its novel cancer drug inobrodib Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma.”
Relapsing / Refractory Multiple Myeloma (RRMM) Companies Actively Working in the Therapeutics Market Include
Allogene Therapeutics, Anaveon AG, Arcellx, Array Biopharma, Bristol-Myers Squibb, Cartesian Therapeutics, Cellectis, Gilead Sciences, Harpoon Therapeutics, Heidelberg Pharma AG, Hrain Biotechnology Co., Ltd., I-MAB Biopharma, Ichnos Sciences, iTeos Therapeutics, Luminary Therapeutics, Novartis, ONK Therapeutics, Oricell Therapeutics, Pfizer, Poseida Therapeutics, Regeneron Pharmaceuticals, Seagen Inc., Sorrento Therapeutics, Takeda, TeneoOne, Trillium Therapeutics Inc., Virtuoso BINco, Inc., Xencor, and others.
Emerging and Marketed Relapsing / Refractory Multiple Myeloma (RRMM) Therapies Covered in the Report Include:
Mezigdomide: Bristol-Myers Squibb
Iopofosine: Cellectar Biosciences, Inc.
ORIC-533: ORIC Pharmaceuticals
Melflufen: Oncopeptides
Idecabtagene vicleucel: Celgene/Bluebird
Isatuximab: Sanofi
JNJ-68284528: Legend Biotech Biotech/Janssen Biotech
GSK2857916: GlaxoSmithKline
Ibrutinib: Pharmacyclics
Xpovio: Karyopharm Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Relapsing / Refractory Multiple Myeloma Competitive Intelligence Analysis
4. Relapsing / Refractory Multiple Myeloma Market Overview at a Glance
5. Relapsing / Refractory Multiple Myeloma Disease Background and Overview
6. Relapsing / Refractory Multiple Myeloma Patient Journey
7. Relapsing / Refractory Multiple Myeloma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Relapsing / Refractory Multiple Myeloma Treatment Algorithm, Current Treatment, and Medical Practices
9. Relapsing / Refractory Multiple Myeloma Unmet Needs
10. Key Endpoints of Relapsing / Refractory Multiple Myeloma Treatment
11. Relapsing / Refractory Multiple Myeloma Marketed Therapies
12. Relapsing / Refractory Multiple Myeloma Emerging Drugs and Latest Therapeutic Advances
13. Relapsing / Refractory Multiple Myeloma Seven Major Market Analysis
14. Attribute Analysis
15. Relapsing / Refractory Multiple Myeloma Market Outlook (In US, EU5, and Japan)
16. Relapsing / Refractory Multiple Myeloma Companies Active in the Market
17. Relapsing / Refractory Multiple Myeloma Access and Reimbursement Overview
18. KOL Views on the Relapsing / Refractory Multiple Myeloma Market
19. Relapsing / Refractory Multiple Myeloma Market Drivers
20. Relapsing / Refractory Multiple Myeloma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Hepatitis A Market
“Hepatitis A Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hepatitis A market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hepatitis A market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
